ABSTRACT. Pentoxifylline (PTXF) is a methylxanthine that modifies leukocyte function and inhibits cytokine release. To evaluate its effects on the cardiovascular manifestations of sepsis secondary to group B streptococci, 14 anesthetized, mechanically ventilated piglets were studied over a 240-min period. Animals were randomly assigned to a treatment group that received a PTXF bolus (20 mg/ kg) followed by a continuous infusion of 5 mg/kg/h before and during group B streptococci (1 X 10%olony forming units/kg/min) administration and a control group that received saline as a placebo. Comparison of the hemodynamic measurements and arterial blood gases during the first 90 min of PTXF treatment with those of the control group resulted in the following 90 min values: systemic arterial blood pressure was significantly higher in the PTXF group mm Hg/L/min/kg; p < 0.001), and these animals were less acidotic as measured by pH (7.07 f 0.2 versus 7.31 +. 0.1; p < 0.05) and base deficit (-15 f 9 versus -5 +-2 mmol/ L; p < 0.05). Median survival time was significantly longer in the PTXF group (210 versus 90 min; p < 0.002). These data demonstrate that PTXF can ameliorate some of the deleterious hemodynamic manifestations of group B streptococci sepsis and result in improved survival in a young animal model. (Pediatr Res 31: 596-600, 1992) Abbreviations CO, cardiac output GBS, group B streptococci PTXF, pentoxifylline PVR, pulmonary vascular resistance Ppa, pulmonary artery pressure Pra, right atrial pressure SVR, systemic vascular resistance Psa, systemic arterial blood pressure During sepsis, bacteria and their products stimulate inflammatory cells, which results in the release of various mediators and cytokines such as tumor necrosis factor-a and IL-I. Tumor
necrosis factor-cu is purported to be responsible for the lethal effect of endotoxin and other bacterial products (1, 2). To some extent, activation of phagocytic cells and release of mediators during sepsis may be considered to be similar to a hypersensitization reaction to bacterial products. Often the resulting intense phagocytic activity can lead to nonspecific injury to surrounding tissue (3).
Traditionally, therapy for sepsis and septic shock has been aimed at eradication of bacteria and at general cardiovascular support. This approach has resulted in only modest improvement in outcome for the neonate. PTXF, a methylxanthine derivative, is an agent that may mitigate the hypersensitization response to infection. This drug diminishes lysosomal enzyme release and superoxide generation by stimulated neutrophils (3, 4) and decreases the production and effects of tumor necrosis factor-cu and IL-1 (2, 5-7). Furthermore, PTXF attenuates tumor necrosis factor-endothelial cell injury in the presence of polymorphonuclear cells (8) . These properties tend to lessen the reaction or overreaction of the animal to a septic challenge.
Based on the above properties, we hypothesized that the cardiovascular effects and consequently survival from bacterial challenge might be modified favorably by PTXF. The purpose of this study was to test this hypothesis in a young animal model of GBS sepsis and to evaluate various dosages of PTXF to elucidate its clinical effectiveness and potential cardiovascular side effects.
MATERIALS AND METHODS
Twenty-six Yorkshire piglets aged 7-10 d were anesthetized with pentobarbital (30 mg/kg, intrapentoneally). A tracheostomy was performed and a 5-mm endotracheal tube placed. Femoral arteries and veins were cannulated and used for measurement of Psa, blood sampling, and infusion of bacteria, fluids, and drugs. The left external jugular vein was cannulated and the catheter advanced into the right atrium for measurement of Pra and injection of ice cold saline, which was used to measured CO. A 5 French Swan-Ganz thermodilution catheter was introduced into the right external jugular vein, advanced under fluoroscopy into the left pulmonary artery, and used to measure Ppa and pulmonary wedge pressures. Heparinized normal saline (10 U/ mL; maximum of 300 U delivered during the experiment) was infused continuously through the pulmonary artery catheter and an infusion of 6 mL/kg/h of 5% dextrose solution was infused through a peripheral vein. Vascular pressures were measured with pressure transducers (model P23-1D; Gould Instruments, Cleveland, OH) and recorded on a multichannel recorder (model 7 polygraph; Grass Instrument Co., Quincy, MA).
The animals were ventilated with a time-cycled, pressurelimited, infant ventilator (Bourns BP 200, Riverside, CA). Arte-rial blood gases in the normal range were obtained by setting peak inflation pressure at I 1 + 1 cm H20, positive end-expiratory pressure at 2 cm H 2 0 , and respiratory rate at 40 breaths/min. Animals were ventilated with room air, and settings were not altered during the study period. Animals were paralyzed with pancuronium bromide using an initial dose of 0.2 mg/kg i.v. followed by a continuous infusion of 0.4 mg/kg/h. Rectal temperature was continuously monitored with a thermistor probe (Yellow Springs Instrument Co., Yellow Springs, OH), and skin temperature was maintained at 38.5"C by a servo-controlled radiant warmer.
Group B P-hemolytic streptococci, type Ia/c. isolated from an infected neonate cared for in the neonatal intensive care unit at Jackson Memorial Hospital were cultured in Todd-Hewitt broth for 18 h at 37°C. The organisms were collected by centrifugation, washed twice in pyrogen-free saline, and resuspended in sterile Ringer's lactate solution with 5% dextrose at a concentration determined by OD measurements to be equivalent to 7.9 x lo9 colony forming units/mL. The bacterial cell suspension was free of endotoxin as determined by a limulus amebocyte lysate test (Associate of Cape Cod, Woods Hole, MA) with a sensitivity of > 0.03 endotoxin units/mL. Bacteria were then infused through a femoral vein at a rate calculated to deliver approximately 1 X 10%olony forming units/kg/min. This infusion was started 30 rnin after the PTXF or placebo infusion was begun and continued until the animal died or 240 min elapsed.
PTXF (20 mg/kg) was mixed with 10 mL of sterile water and given as an initial rapid infusion over 10 rnin followed by a continuous infusion throughout the study. To determine the dose of PTXF to be used as a continuous infusion, the following dosage regimens were tested: 20 mg/kg/h (n = 6), 10 mg/kg/h (n = 2), and 5 mg/kg/h (n = 4). Because the results showed marked hypotension after 90 rnin of PTXF plus GBS infusion using a continuous infusion of either 10 or 20 mg/kg/h, but not with 5 mg/kg/h (Table I) , the latter was chosen for the study.
Assays of plasma PTXF levels were performed in five animals receiving a continuous infusion of 20 mg/kg/h of PTXF and in four animals receiving 5 mg/kg/h at 15, 45, 60, and 120 min after the beginning of PTXF infusion, using methods described previously by Burrows (9).
Additional animals were randomly assigned to a treatment group (n = 7) (mean + SD; weight, 3687 f 577 g; age, 9 + I d)
that received PTXF as a 20-mg/kg bolus over 10 rnin followed by a continuous infusion of 5 mg/kg/h throughout the remainder of the study. Seven piglets (weight, 3 17 1 f 5 15 g; age, 8 f 1 d) were assigned to the control group and received 10 mL of normal saline over the same time period, followed by a continuous infusion of normal saline at the same rate as the continuous infusion of PTXF. After a 60-min stabilization period, hemodynamic measurements (Psa, Ppa, pulmonary wedge pressure, CO, and Pra) and arterial blood gases were obtained before any intervention (baseline 1). The PTXF or placebo bolus was then started, followed by a continuous infusion. Before the beginning of bacterial infusion, all measurements were repeated and this was considered baseline 2. Thirty min after the start of PTXF or placebo, GBS infusion was initiated. Hemodynamic measurements and blood gases were obtained 15 rnin after the beginning of bacterial infusion and were subsequently measured at 30 and 60 min and then every 30 min until death or until 240 min had elapsed. PVR, SVR, and stroke volume were calculated.
Handling and care of animals were in accordance with the guidelines of the National Institutes of Health. and this study protocol was approved by the Animal Care Committee of the University of Miami, School of Medicine.
Dependent variables in this study include Ppa, Psa, pulmonary wedge pressure, stroke volume, CO, pH. arterial Poz, arterial Pco~, base deficit, PVR, and SVR. Data are expressed as mean + SD. Repeated measures analysis of covariance was used to compare the pattern of response to treatment against the control response, both over time and independent of time. Significant mortality in the control group prevented us from analyzing data after 120 min, and, in fact, several control animals died between 90 and 120 min. For this reason, analyses were performed using both 90 and 120 min. In general, the two analyses supported each other, and p values presented in the text are from the 90-rnin comparisons except in the dose-response study, in which they include values up to 120 min. These values are HuynhFeldt corrected for correlations between the same animals at different times. Survival time was compared between groups using the Mann-Whitney U test because all animals were followed either to death or to the end of the study.
RESULTS
In the preliminary study, which evaluated various continuous infusion doses of PTXF, it was noted that by 120 min Psa decreased approximately 38% when an infusion of either 10 or 20 mg of PTXF/kg/h was used (Table 1 ) . In contrast mean Psa was significantly higher in the group treated with 5 mg/kg/h compared with those receiving 20 mg/kg/h ( p < 0.05) ( Table 1) .
Serum PTXF levels were 13 080 + 3 306, 25 700 + 7 00 1, and 33 190 + 2 688 ng/mL at 15, 60, and 120 min, respectively, for animals receiving 20 mg/kg/h and 17 830 2 12 700, 10 720 + 5 6 18, and 8 722 + 3 00 l ng/mL for those receiving 5 mg/kg/h.
Values at 60 and 120 rnin were significantly higher ( p < 0.02 and 0.002, respectively) in those animals receiving the 20-mg/ kg/h infusion. Furthermore, four out of six animals receiving an infusion of 20 mg of PTXF/kg/h died within 150 rnin of starting GBS as opposed to no deaths in the group receiving 5 mg/kg/h during the same time period.
As a result of these pilot findings, the main study was performed comparing control animals with a group receiving a continuous infusion of PTXF at a rate of 5 mg/kg/h. Age and weight were not significantly different between treatment and control animals. Hemodynamic measurements at baseline were also comparable between groups. Furthermore, when baseline values before and after PTXF or placebo bolus were evaluated, no significant differences were noted (Table 2) .
Mean Psa initially increased in both groups, but by 120 rnin it had dropped 33% from baseline in the control group. However, mean Psa in the PTXF-treated animals was maintained and was significantly higher after 60 min of GBS infusion compared with control animals (time and treatment interaction. p < 0.005) (Fig.   1 ). CO initially decreased comparably in both groups with GBS administration but was significantly higher (time and treatment interaction, p < 0.005) over time (15 to 90 min after bacteria infusion started) in the PTXF-treated animals (Fig. 1) . The net result was a 20% decline in CO in PTXF-treated animals compared with a 65% decrease for control animals at 120 min. Heart rate was not significantly different during the bacterial infusion; however, stroke volume continued to rise in the PTXF-treated group after it had dropped in the control group (time and treatment interaction, p < 0.02) ( Table 2 ).
Ppa and Pra were not significantly different between groups (Table 2) . However, pulmonary wedge pressure showed a trend toward being higher in the control group ( p = 0.057). After GBS infusion, PVR remained lower in the PTXF group (treatment effect, p < 0.001) than in control animals (Fig. 2) . Also, SVR was lower in the PTXF-treated than in the control group (treatment effect, p < 0.05) ( Table 2 ).
Arterial 0 2 and C 0 2 tension levels were also not significantly different. However, pH and base deficit reflected significantly less acidosis (time treatment interaction, p < 0.05) in the PTXF group over the study period (Table 3) .
At 120 min, 100% of the PTXF-treated animals were alive compared with 40% in the control group. The PTXF-treated animals survived significantly longer than the control animals (median 2 10 versus 90 min) ( p < 0.002) (Fig. 3) .
DISCUSSION
The results of the present study suggest that pretreatment with PTXF results in substantial protection against the hemodynamic effects of an infusion of GBS in a young animal model. Specifically, our data indicate that pretreatment with PTXF modifies the cardiovascular manifestations of sepsis, such as hypotension and diminished CO, and improves survival in this highly lethal model of sepsis. The mechanisms by which PTXF ameliorates these hemodynamic manifestations are unclear, which is in part a reflection of the uncertainty concerning the mechanism of septic injury.
Recently, Gibson er al. (2) noted that PTXF attenuated GBS-
induced tumor necrosis factor production in a septic piglet model and that its administration resulted in mild improvement in Ppa, PVR, and arterial Po2. They also noted that animals receiving GBS plus PTXF had significantly greater systemic hypotension after 4 h of GBS infusion when compared with those animals receiving GBS alone. The methods and results of the present study differ in the following ways. First, Gibson et al. (2) used an infusion of 20 mg/kg/h. The hypotension seen in animals receiving this dose is anticipated by our preliminary dose-response study and may in part be explained by elevated PTXF 0-OCONTROL A-APTXF TIME (minutes) Fig. 3 . Length of survival time after bacterial infusion was significantly longer in the PTXF-treated animals ( p < 0.002) levels. Second, our model is a highly lethal one that to some extent mimics the rapid progression and severe hemodynamic instability seen in the severely ill septic neonate. As a consequence, the nature of our model and dose of PTXF used allowed detection of an overall beneficial effect of PTXF on blood pressure, CO, PVR, and length of survival.
Published animal studies suggest that a continuous infusion of a dose of 20 mg of PTXF/kg/h may be beneficial and necessary during sepsis to inhibit tumor necrosis factor-induced pulmonary vasoconstriction in the septic piglet (2). However, data from the present study revealed that the use of higher continuous infusion doses of PTXF (20 mg/kg/h) resulted in earlier death and significant hypotension, a finding confirmed by other studies (2, 10). This may be related to an exaggeration of the late sepsisinduced increase in prostacyclin (1 I ) secondary to PTXF (2) or to a direct toxic effect of PTXF accumulation during sepsis. This is supported by our findings that PTXF levels in animals receiving 20 mg/kg were two to three times higher than those in the 5-mg/kg/h group. Hypotension or other adverse hemodynamic changes were not observed when a bolus of PTXF was given before infusing bacteria in this study. Longer infusions of PTXF are described by Gibson et al. (2) and appear to be well tolerated in the hemodynamically stable animal.
Plasma PTXF levels achieved in this model are higher than those reported in the literature (1 2). Reasons for this may include the following: I ) the doses of PTXF used in experimental models of sepsis have been considerably higher than those traditionally given to humans to treat intermittent claudication, and 2) the model reported in this study uses young animals, which may have different pharmacokinetic characteristics and drug metabolism than the adult ( i e. lower clearance and greater volume of distribution).
During the GBS infusion in the present study, mean Psa fell significantly in the control group, whereas that of the PTXFtreated animals remained stable. An explanation for the beneficial effects of low doses of PTXF on mean Psa during sepsis is unclear. PTXF is known to inhibit phosphodiesterase and increase intracellular concentrations of cAMP (13). Increases in cAMP secondary to adrenergic stimulation have been associated with improvement in CO (6), an effect that may contribute to the prevention of hypotension. Furthermore, PTXF has been shown to decrease the release of tumor necrosis factor-a (2), which has been associated with depression of CO as well as hypotension (14, 15). This observation is supported by the work of Lilly et al. (6) , who demonstrated that PTXF-treated animals exposed to tumor necrosis factor had significantly higher mean Psa compared with controls.
In the present study, CO decreased approximately 20% in the PTXF-treated animals versus 65% in control animals. This was most likely related to increased stroke volume in the PTXF 
. -
In summary, the results of the present study suggest that PTXF at the dose used in this study modifies the detrimental changes in Psa, CO, pulmony wedge pressure, PVR, and acid-base status and prolongs survival during group B streptococcal infusion in the piglet. Furthermore, PTXF may be beneficial in neonatal sepsis after more extensive trials with the caveat that negative hemodynamic effects are associated with increased dosage.
